logo-loader
RNS
Verona Pharma

Verona Pharma plc : Notice of Results

to Announce Interim Results for Six Months Ended and Provide Clinical Development UpdateVerona PharmaJune 30, 2018

, (GLOBE NEWSWIRE) -- (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for respiratory diseases, announces that it will report its audited financial results for the six months ended on .LONDONJuly 26, 2018June 30, 2018Tuesday, August 7, 2018Verona Pharma plc

will host an investment community conference call at ( British ) on to discuss the six months financial results and provide a clinical development update.Verona Pharma8:00 a.m. Eastern Daylight Time1:00 p.m.Tuesday, August 7, 2018Summer Time

Analysts and investors may participate in the conference call by utilizing the conference ID: 7830929 and dialing the following numbers:

Those interested in listening to the conference call live via the internet may do so by visiting the "Investors" page of website at  and clicking on the "Events and presentations" link.Verona Pharma'swww.veronapharama.com

A webcast replay of the conference call (audio) will be available for 30 days on the "Investors" page of website at .Verona Pharma'swww.veronapharma.com

AboutVerona Pharma plc

is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. product candidate, RPL554, is a first-in-class, inhaled, dual inhibitor of the enzymes phosphodiesterase 3 and 4 that acts as both a bronchodilator and an anti-inflammatory agent in a single compound. In clinical trials, treatment with RPL554 has shown clinically meaningful and statistically significant improvements in lung function and clinical symptoms as compared to placebo, and has shown statistically significant improvements in lung function when administered in addition to frequently used short- and long-acting bronchodilators as compared to such bronchodilators administered as a single agent. is developing RPL554 for the treatment of chronic obstructive pulmonary disease (COPD), cystic fibrosis (CF), and potentially asthma.Verona PharmaVerona Pharma'sVerona Pharma

For further information, please contact:

  • 800-458-4121 or 929-477-0324 for callers inthe United States
  • 0800 279 7204 or 44 (0)330 336 9411 for callers in theUnited Kingdom
  • 0800 101 1732 or 49 (0)69 2222 2018 for calls inGermany
Verona Pharma plcTel: +44 (0)20 3283 4200
, Chief Executive OfficerJan-Anders Karlssoninfo@veronapharma.com
  
(Nominated Adviser and Broker)Stifel Nicolaus Europe Limited
UK
Tel: +44 (0) 20 7710 7600
/ /Stewart WallaceJonathan SeniorBen Maddison 
  
FTI Consulting ( Media and Investor enquiries)UKTel: +44 (0)20 3727 1000
/Simon ConwayNatalie Garland-Collinsveronapharma@fticonsulting.com
  
(US Media and Investor enquiries)ICR, Inc. 
James HeinsTel: +1 203-682-8251
James.Heins@icrinc.com
Stephanie CarringtonTel. +1 646-277-1282
Stephanie.Carrington@icrinc.com
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.Source: via Globenewswire

Verona Pharma plc




NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of...

FOR OUR FULL DISCLAIMER CLICK HERE

3 min read